Tenet Healthcare Corp

Tenet Healthcare Corp(THC)股票分析

$268.450

-2.174 (-0.81%)收盘时

Loading chart…
最高
272.540
开盘
268.690
成交量加权均价
269.17
成交量
460.00K
市值
13.51B
最低
266.530
成交额
123.82M
企业价值/息税折旧摊销前利润(TTM)
6.56

Tenet Healthcare Corporation is a diversified healthcare services company. The Company's segments include Hospital Operations and Services (Hospital Operations) and Ambulatory Care. The Hospital Operations segment consists of its acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. The Company's subsidiaries operate approximately 50 hospitals serving primarily urban and suburban communities in eight states. The Hospital Operations segment also includes around 132 outpatient facilities, including urgent care centers, imaging centers, off-campus hospital emergency department and micro hospitals. It also provides revenue cycle management and value based care services. Ambulatory Care segment, through its USPI Holding Company, Inc. subsidiary, holds ownership interests in approximately 533 ambulatory surgery centers, and 26 surgical hospitals in 37 states. It also operates a Global Business Center in the Philippines.

AI 分析 of Tenet Healthcare Corp (THC)

买入

Tenet Healthcare Corp appears to be a good buy right now due to its strong financial performance and positive market sentiment. The current price is $268.45, and the company has shown a year-to-date change of +34.60%. Additionally, the forward P/E ratio is 12.53, which is attractive compared to the industry average. However, the main risk is the insider selling, where a director sold shares at $258.80, representing 5% of her equity stake, indicating some caution among insiders.

分析师评级(16)

-9.52% 下跌空间
持有
4 买入
12 持有
0 卖出
当前: 268.45
最低
229.00
平均
242.89
最高
260.00

BMO Capital

2026-09-22

目标价

$265

Market Perform

BofA

2026-08-10

目标价

$295

买入

Mizuho

2026-08-10

目标价

$290

跑赢大盘

Wells Fargo

2026-08-03

目标价

$281

增持

Goldman Sachs

2026-07-28

目标价

$305

买入

估值指标

Tenet Healthcare Corp(THC)当前预期市盈率为 12.53,5 年平均预期市盈率为 11.91。

预期市盈率

合理
5 年均值 P/E
11.91
当前P/E
12.53
高估
13.94
低估
9.87

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
6.92
当前EV/EBITDA
6.56
高估
7.53
低估
6.32

预期市销率

高估
5 年均值 P/S
0.54
当前P/S
0.96
高估
0.75
低估
0.34

Alphio AI 对 THC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%THC

$152.71

情景价格

基

基准

基准 · 50%THC

$138.03

情景价格

悲

悲观

悲观 · 25%THC

$113.61

情景价格

持有 THC 的大户

M

Meridiem Capital Partners LP

+ 持有THC

+6.92%

3个月收益率

M

Manning & Napier Advisors, LLC

+ 持有THC

+2.87%

3个月收益率

C

Crake Asset Management LLP

+ 持有THC

+1.78%

3个月收益率

P

Pale Fire Capital SE

+ 持有THC

-0.41%

3个月收益率

B

BW Gestao de Investimentos Ltda.

+ 持有THC

-2.61%

3个月收益率

M

Moore Capital Management, LP

+ 持有THC

-6.01%

3个月收益率

THC 常见问题 —— 由 Alphio AI 解答

Tenet Healthcare Corporation is a diversified healthcare services company. The Company's segments include Hospital Operations and Services (Hospital Operations) and Ambulatory Care. The Hospital Operations segment consists of its acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. The Company's subsidiaries operate approximately 50 hospitals serving primarily urban and suburban communities in eight states. The Hospital Operations segment also includes around 132 outpatient facilities, including urgent care centers, imaging centers, off-campus hospital emergency department and micro hospitals. It also provides revenue cycle management and value based care services. Ambulatory Care segment, through its USPI Holding Company, Inc. subsidiary, holds ownership interests in approximately 533 ambulatory surgery centers, and 26 surgical hospitals in 37 states. It also operates a Global Business Center in the Philippines. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).

Tenet Healthcare Corp appears to be a good buy right now due to its strong financial performance and positive market sentiment. The current price is $268.45, and the company has shown a year-to-date change of +34.60%. Additionally, the forward P/E ratio is 12.53, which is attractive compared to the industry average. However, the main risk is the insider selling, where a director sold shares at $258.80, representing 5% of her equity stake, indicating some caution among insiders.

16 analysts cover THC: 4 rate it Buy, 12 Hold and 0 Sell. The average price target is 242.89.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易